Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY19 results · Apr–Jun 2018
Ajanta Pharma reported revenue from operations of ₹510.99 crore and net profit of ₹105.79 crore for Q1 FY19 (Apr–Jun 2018), on a consolidated basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 510.99 | — | — | — | — |
| Other income | 8.13 | — | — | — | — |
| Total income | 519.12 | — | — | — | — |
| Profit before tax | 148.28 | — | — | — | — |
| Net profit for the period | 105.79 | — | — | — | — |
| EPS, basic (₹) | 12.02 | — | — | — | — |
| Net margin (%) | 20.7 | — | — |
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 441.95 | — | — | — | — |
| Other income | 69.06 | — | — | — | — |
| Total income | 511.01 | — | — | — | — |
| Profit before tax | 193.36 | — | — | — | — |
| Net profit for the period | 150.82 | — | — | — | — |
| EPS, basic (₹) | 17.14 | — | — | — | — |
| Net margin (%) | 34.1 | — | — |
Consolidated
- Filed with BSE
- 31 Jul 2018, 18:07 IST
- Board meeting
- 31 Jul 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2018, 18:07 IST
- Board meeting
- 31 Jul 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE